Literature DB >> 7038329

Urinary tract antiseptics.

A R Mayrer, V T Andriole.   

Abstract

The urinary tract antiseptics discussed herein have specific advantages and disadvantages. All share a pharmacokinetic fate that makes them effective in treating acute, uncomplicated symptomatic bladder bacteriuria. Nitrofurantoin appears to be the most versatile because it is effective against upper tract infection, recurrent bacteriuria, and as a long-term suppressive agent in children and pregnant patients with only a low incidence of the development of resistance. Methenamine, when used with proper understanding of it pharmacokinetic behavior, is also effective in females with uncomplicated recurrent bacteriuria including those with multiply resistant pathogens, as well as a prophylactic agent in males with recurrent infection. There is little evidence that methenamine combined with mandelic or hippuric acid confers any pharmacologic or therapeutic advantage over the use of methanamine base alone. Nalidixic acid and oxolinic acid, in addition to effectiveness in treating uncomplicated acute lower urinary tract infections, may be effective in some patients with recurrent infections, but requires careful sensitivity monitoring of pathogens for the development of resistance. Finally, in a society whose economic pressures are such that it may not be cost-effective to use sulfamethoxazole-trimethoprim for urinary tract prophylaxis--unless two or more acute infections occur per year--the use of these urinary antiseptics may offer increasing advantages now and in the future.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7038329     DOI: 10.1016/s0025-7125(16)31453-5

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  9 in total

Review 1.  Current concepts in the treatment of genitourinary tract disorders in the older individual.

Authors:  A Atala; M Amin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 2.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

3.  Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin.

Authors:  W R Bowie; V Willetts; P J Jewesson
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 4.  Methenamine hippurate for preventing urinary tract infections.

Authors:  Bon San B Lee; Tushar Bhuta; Judy M Simpson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

5.  Recurrent Urinary Tract Infections Management in Women: A review.

Authors:  Ahmed Al-Badr; Ghadeer Al-Shaikh
Journal:  Sultan Qaboos Univ Med J       Date:  2013-06-25

Review 6.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 7.  Recurrent urinary tract infections in women.

Authors:  Abdullatif Aydin; Kamran Ahmed; Iftikhar Zaman; Muhammad Shamim Khan; Prokar Dasgupta
Journal:  Int Urogynecol J       Date:  2014-11-20       Impact factor: 2.894

8.  Use of methenamine hippurate to prevent urinary tract infections in community adult women: a systematic review and meta-analysis.

Authors:  Mina Bakhit; Natalia Krzyzaniak; Joanne Hilder; Justin Clark; Anna Mae Scott; Chris Del Mar
Journal:  Br J Gen Pract       Date:  2021-06-24       Impact factor: 6.302

Review 9.  Urinary tract infection and subclinical bacteriuria in cats: A clinical update.

Authors:  Roswitha Dorsch; Svenja Teichmann-Knorrn; Heidi Sjetne Lund
Journal:  J Feline Med Surg       Date:  2019-10-10       Impact factor: 2.015

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.